Catalyst Pharmaceuticals Inc Revenue Growth Rates (CPRX), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Catalyst Pharmaceuticals Inc   (NASDAQ: CPRX)
 

CPRX's Revenue Growth by Quarter and Year

Catalyst Pharmaceuticals Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

CPRX Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -
2nd Quarter June -
1st Quarter March 149.39
FY 149.39

CPRXs Annual Revenue
Catalyst Pharmaceuticals Inc 's Revenue in the fiscal year 2025 $ 588.99 millions
Catalyst Pharmaceuticals Inc 's Revenue in the fiscal year 2024 $ 491.73 millions
Catalyst Pharmaceuticals Inc 's Revenue in the fiscal year 2023 $ 398.20 millions
Catalyst Pharmaceuticals Inc 's Revenue in the fiscal year 2022 $ 214.20 millions
Catalyst Pharmaceuticals Inc 's Revenue in the fiscal year 2021 $ 140.83 millions




CPRX Revenue first quarter 2026 Y/Y Growth Comment
Catalyst Pharmaceuticals Inc reported Revenue growth of 5.64% year on year in the first quarter 2026, to $ 149.39 millions, this is lower than Catalyst Pharmaceuticals Inc 's recent average Revenue improvement of 37.49%.

Looking into first quarter 2026 results within Major Pharmaceutical Preparations industry 76 other companies have achieved higher Revenue growth. While Catalyst Pharmaceuticals Inc ' s Revenue increase of 5.64% ranks overall at the positon no. 1304 in the first quarter 2026.


CPRX Revenue ( Y/Y Growth %) 2026
 2025 2024 2023
4th Quarter December - 7.61 % 28.26 % 81.98 %
3rd Quarter September - 15.3 % 25.33 % 79.4 %
2nd Quarter June - 19.44 % 23.23 % 87.5 %
1st Quarter March 5.64 % 43.56 % 15.39 % 98.12 %
FY   - 19.77 % 23.49 % -

Financial Statements
Catalyst Pharmaceuticals Inc 's first quarter 2026 Revenue $ 149.39 millions CPRX's Income Statement
Catalyst Pharmaceuticals Inc 's first quarter 2025 Revenue $ 141.42 millions Quarterly CPRX's Income Statement


CPRX Revenue (Quarter on Quarter Growth %)

 2026
 2025 2024 2023
4th Quarter December - 2.84 % 10.19 % 7.67 %
3rd Quarter September - 1.25 % 4.88 % 3.12 %
2nd Quarter June - 3.63 % 24.57 % 16.65 %
1st Quarter March -2.11 % -0.28 % -10.91 % 40.5 %
FY (Year on Year)   - 19.77 % 23.49 % -


Back to CPRX Growth rate Comparisons >> Back to CPRX Growth rate Comparisons >>


Revenue first quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #77
Healthcare Sector #226
Overall #1304

Revenue Y/Y Growth Statistics
High Average Low
85.9 % 37.49 % 0.96 %
(Dec 31 2023)   (Mar 31 2021)
Revenue first quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #77
Healthcare Sector #226
Overall #1304
Revenue Y/Y Growth Statistics
High Average Low
85.9 % 37.49 % 0.96 %
(Dec 31 2023)   (Mar 31 2021)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Catalyst Pharmaceuticals Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
2389.69 % 93.24 % -10.91 %
(Mar 31 2019)  


CPRX's I. Quarter Q/Q Revenue Comment
In the I. Quarter 2026 Catalyst Pharmaceuticals Inc disclosed fall in Revenue from the fourth quarter by -2.11% to $ 149.39 millions, from $ 152.61 millions achived in the previous reporting period.

But that's not important problem, as Catalyst Pharmaceuticals Inc 's Revenue generally seem to plunge in this quarter.

Within Major Pharmaceutical Preparations industry 87 other companies have achieved higher Revenue quarter on quarter growth. While Catalyst Pharmaceuticals Inc 's Revenue growth quarter on quarter, overall rank is 2008.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #88
Healthcare Sector #249
Overall #2008
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #88
Healthcare Sector #249
Overall #2008
Revenue Q/Q Growth Statistics
High Average Low
2389.69 % 93.24 % -10.91 %
(Mar 31 2019)  


CPRX's I. Quarter Q/Q Revenue Comment
In the I. Quarter 2026 Catalyst Pharmaceuticals Inc disclosed fall in Revenue from the fourth quarter by -2.11% to $ 149.39 millions, from $ 152.61 millions achived in the previous reporting period.

But that's not important problem, as Catalyst Pharmaceuticals Inc 's Revenue generally seem to plunge in this quarter.

Within Major Pharmaceutical Preparations industry 87 other companies have achieved higher Revenue quarter on quarter growth. While Catalyst Pharmaceuticals Inc 's Revenue growth quarter on quarter, overall rank is 2008.


Catalyst Pharmaceuticals Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Mar 31 2026)		 12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Sep 30 2025)		 12 Months Ending
(Jun 30 2025)		 12 Months Ending
(Mar 31 2025)
Cumulative Revenue 12 Months Ending $ 596.96 $ 588.99 $ 578.20 $ 558.50 $ 534.65
Y / Y Revenue Growth (TTM) 11.65 % 19.78 % 25.56 % 28.55 % 29.97 %
Year on Year Revenue Growth Overall Ranking # 563 # 287 # 232 # 243 # 74
Seqeuential Revenue Change (TTM) 1.35 % 1.87 % 3.53 % 4.46 % 8.73 %
Seq. Revenue Growth (TTM) Overall Ranking # 1660 # 1505 # 1202 # 900 # 1166


Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Mar 31 2026 period, Catalyst Pharmaceuticals Inc 's cumulative twelve months Revenue were $ 597 millions, company would post below average annual Revenue growth of 8.73% year on year, if the fiscal year would end at Mar 31 2026.
A slow-down in the Catalyst Pharmaceuticals Inc 's Revenue growth from the 152.61% growth in Dec 31 2025.

In the Healthcare sector 126 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 287 to 563.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 89
Healthcare Sector # 127
Overall # 563

Revenue TTM Y/Y Growth Statistics
High Average Low
85.9 %
 37.49 %
0.96 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 89
Sector # 267
S&P 500 # 1660
Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Mar 31 2026 period, Catalyst Pharmaceuticals Inc 's cumulative twelve months Revenue were $ 597 millions, company would post below average annual Revenue growth of 0.96% year on year, if the fiscal year would end at Mar 31 2026.
A slow-down in the Catalyst Pharmaceuticals Inc 's Revenue growth from the 152.61% growth in Dec 31 2025.

In the Healthcare sector 126 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 287 to 563.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 89
Healthcare Sector # 127
Overall # 563

Revenue TTM Y/Y Growth Statistics
High Average Low
85.9 %
37.49 %
0.96 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 89
Sector # 267
S&P 500 # 1660




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
CPRX's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue fall for the quarter ending Mar 31 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Mar 31 2026
Acadia Pharmaceuticals Inc 9.72%$ 9.719 millions
Sotera Health Company9.68%$ 9.683 millions
Universal Health Services Inc 9.65%$ 9.646 millions
Earth Science Tech Inc 9.46%$ 9.462 millions
Bausch and Lomb Corp9.41%$ 9.411 millions
Zimmer Biomet Holdings Inc 9.30%$ 9.303 millions
Avanos Medical Inc 9.23%$ 9.233 millions
Quest Diagnostics Inc9.16%$ 9.163 millions
Encompass Health Corporation9.01%$ 9.015 millions
International Stem Cell Corporation8.74%$ 8.736 millions
Warby Parker Inc 8.55%$ 8.548 millions
Iqvia Holdings Inc 8.41%$ 8.410 millions
Alpha Pro Tech Ltd 8.39%$ 8.393 millions
Nature s Sunshine Products inc 8.33%$ 8.331 millions
Viatris Inc 8.07%$ 8.072 millions
U S Physical Therapy Inc7.89%$ 7.888 millions
Vertex Pharmaceuticals Inc7.82%$ 7.823 millions
Abbott Laboratories7.78%$ 7.781 millions
Evolus Inc 7.75%$ 7.748 millions
Neuronetics Inc 7.61%$ 7.612 millions
Acadia Healthcare Company Inc 7.57%$ 7.566 millions
Merit Medical Systems Inc7.54%$ 7.542 millions
Biocryst Pharmaceuticals Inc 7.48%$ 7.475 millions
Addus Homecare Corp7.46%$ 7.462 millions
Amarin Corp Plcuk7.41%$ 7.414 millions
Steris Plc7.28%$ 7.279 millions
Mettler toledo International Inc 7.17%$ 7.172 millions
Ge Healthcare Technologies Inc 7.17%$ 7.170 millions
Bioventus Inc 7.08%$ 7.081 millions
Ardent Health Inc 6.99%$ 6.989 millions


About Catalyst Pharmaceuticals Inc Revenue Growth Rates (CPRX), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Catalyst Pharmaceuticals Inc (CIK 1369568).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001369568-26-000002
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Catalyst Pharmaceuticals Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.